Opdivo, from Bristol-Myers Squibb, which harnesses the body’s own immune system to attack tumors, was approved after strong results in a study.
By ANDREW POLLACK, NY Times: Politics
Wed, 03/04/2015 - 3:49pm
Opdivo, from Bristol-Myers Squibb, which harnesses the body’s own immune system to attack tumors, was approved after strong results in a study.